 CAMBRIDGE, Mass., May 13, 2021 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. 